Automatic Breast Ultrasound Imaging System Market: Strategic Imperatives for 2026 — A PW Consulting Insight

As healthcare providers, medical device manufacturers, and investors plan for the coming fiscal year, decision-makers require not only numbers but actionable context that links regulatory shifts, reimbursement dynamics, and technological inflection points to executable commercial strategies. PW Consulting’s newest market research—covering historical performance from 2020–2025 (base year 2025) and a forward-looking forecast for 2026–2032—provides that bridge for the Automatic Breast Ultrasound (ABUS) imaging systems market. Our analysis shows a clearly accelerating market, with the sector growing at a compound annual growth rate (CAGR) of 9.2% and an expected expansion from approximately USD 685.0 Million in 2025 to roughly USD 1,268.4 Million by 2032.
Photographic Continuous Lighting Equipment Market

Why this report matters for 2026 decision cycles

• Timing of regulatory and reimbursement shifts: Changes that became effective in early 2026 materially alter payment economics and thus product adoption curves for supplemental breast screening tools.
• Product and platform innovation: The market is experiencing a new wave of hardware, workflow and AI-enabled software introductions—creating winners and laggards on the basis of integration speed and go-to-market execution.
• Consolidation and competitive concentration: The market structure demonstrates significant concentration among a few leading OEMs, creating both opportunities for challengers and risks of supplier lock-in for customers.
• Provider capital allocation choices: Hospitals, imaging centers and point-of-care clinics must weigh acquisition cost, operational throughput and reimbursement realization to justify purchases in 2026.

Market snapshot (actionable headline figures)

PW Consulting’s base-year calibration finds the ABUS market at approximately USD 685.0 Million in 2025. Under our central-case assumptions, the market will grow at a 9.2% CAGR across the 2026–2032 forecast window, reaching an estimated USD 1,268.4 Million by 2032. This trajectory reflects accelerating adoption as technological maturation, reimbursement clarity and novel form-factors expand the addressable patient population and clinical use cases.
Anchor Channel System Market

Dynamics shaping near-term adoption

• Regulatory endorsement for adjunct use: The FDA’s approvals of multiple ABUS platforms for use as adjuncts to mammography in asymptomatic women with dense breasts continue to underpin clinical acceptance and payer consideration. These clearances reduce clinical ambiguity and enable standardized protocols in high-volume screening settings.
• Reimbursement mechanics: ABUS exams are billed using CPT code 76641 where applicable, providing existing billing infrastructure for organizations that integrate ABUS into supplemental screening workflows. Importantly, policy evolution at the state level—exemplified by Massachusetts’ expanded insurance coverage effective January 2026—creates near-term pockets of improved economics and real-world case studies for broader payor engagement.
• Technology divergence: The market is bifurcating along lines of system architecture and clinical workflow. Traditional automated volume scanners for full-breast, 3D acquisitions remain core to radiology departments and diagnostic centers. At the same time, new entrants with wearable and point-of-care platforms are lowering the access barrier for outpatient clinics and community screening programs.
• AI and reading efficiency: Concurrent-reading AI/CAD solutions—already moving through regulators and payer acceptance—are materially changing the labor economics of ABUS. Systems that tightly integrate hardware and validated AI workflows demonstrate shorter time-to-interpretation and improved reader concordance, strengthening value propositions for high-throughput sites.

Competitive landscape — reading the strategic plays

The ABUS market is characterized by a mix of large global OEMs with comprehensive portfolios and agile innovators focusing on differentiated clinical workflows. Market concentration metrics indicate that the top three players capture roughly 65% of market revenue, while the top five approach over 80%—a structure that rewards scale, channel breadth and installed-base services.
Polydextrose Market

• GE HealthCare (Chicago, Illinois, USA) — With the Invenia ABUS platform and the recent launch of an AI-enhanced Invenia ABUS Premium (March 2025), GE is doubling down on faster scanning and workflow efficiency as the primary lever to protect and extend market share. Its strengths lie in a broad installed base, strong reimbursement guidance, and strategic partnerships with AI developers and imaging networks.
• Siemens Healthineers (Erlangen, Germany) — Positioned with volume-scanning systems such as the ACUSON S2000 ABVS, Siemens competes on image quality, integration into enterprise imaging systems, and cross-modality workflow. Its approach is focused on aligning ABUS with mammography and tomosynthesis workflows in hospital and large outpatient settings.
• Delphinus Medical Technologies (Novi, Michigan, USA) — Delphinus’ SoftVue offers a differentiated whole-breast water-bath tomography method that emphasizes patient comfort and compression-free imaging. The company’s programmatic installations—such as the March 2025 implementation with a regional radiology association—highlight a service-led commercialization play targeting high-density screening cohorts.
• iSono Health (South San Francisco, USA) — iSono’s entry with a wearable, portable ATUSA platform (commercial launch January 2026) points to a disruptive access strategy: decentralize screening to point-of-care clinics and community settings. The success of this approach will hinge on validated clinical equivalence, practical reimbursement capture, and streamlined training models.
• SonoCiné and other innovators — Smaller suppliers and niche players continue to iterate on whole-breast automation and ergonomics, serving as important sources of clinical innovation and potential acquisition targets for larger OEMs seeking product portfolio breadth.
• QView Medical (Silicon Valley, USA) — As an AI-CAD vendor with FDA PMA approval for concurrent reading, QView exemplifies the emergent software layer that can be OEM-neutral or preferentially partnered—creating new routes to market and differentiation beyond hardware alone.

Operational and commercial implications for 2026

• For OEMs: Prioritize integrated AI workflows and validated clinical data that demonstrate throughput gains and improved sensitivity in dense-breast populations. Investment in service capability and regional reimbursement expertise will accelerate installations and reduce sales friction.
• For imaging providers: Evaluate ABUS adoption through a total-cost-of-ownership lens that includes interpretation time, reimbursement capture (CPT 76641 utilization), and incremental diagnostic yield. Pilot programs in states with expanded coverage (e.g., Massachusetts) can de-risk broader deployment.
• For payers and health systems: Targeted coverage policies that incentivize appropriate use in dense-breast screening pathways can reduce downstream treatment costs through earlier detection—anchoring the value case for broader coverage.
• For investors and corporates: The high concentration ratio suggests M&A opportunities for strategic acquirers seeking to combine hardware, AI, and service capabilities. Watch for tuck-in opportunities among innovators with unique form factors or AI-validated clinical outcomes.

Practical contents of the PW Consulting report (what you’ll get)

Our full report goes beyond headline estimates to provide operationally oriented intelligence that executives can act on in 2026. Highlights include:

• Scenario-based revenue forecasts and sensitivity analysis across our 2026–2032 horizon.
• Actionable go-to-market playbooks for OEMs, including channel segmentation, pricing levers, and service economics.
• Provider decision frameworks and ROI templates that quantify break-even points for hospitals, imaging centers and ambulatory clinics.
• Regulatory and reimbursement trackers with state-level coverage updates, coding guidance, and payer engagement templates.
• Detailed company profiles, product roadmaps, and competitive benchmarking—covering clinical differentiation, IP posture, and partnership opportunities.

To respect the “trailer” principle of this briefing—showing strategic depth while preserving the tactical granularity that drives commercial action—we deliberately withhold detailed regional, technology and end-user splits here. Those detailed segmentations, pricing matrices, and install-base forecasts are included in the full report and the accompanying downloadable data models.

Recommendations for C-suite teams preparing 2026 plans

• Close the payer conversation: Use early 2026 policy wins as leverage to run pilot projects that demonstrate revenue capture and downstream clinical impact. Data from these pilots will be decisive in broader procurement approvals.
• Partner on AI early: For OEMs, integrating validated CAD partners or developing in-house AI that can demonstrably reduce reading time is table stakes for competing in high-volume screening programs.
• Re-think channel strategy: Expect a widening buyer base—beyond radiology departments to primary care and outpatient clinics—especially as wearable and point-of-care systems commercialize. Channel economics and training models must adapt accordingly.
• Plan for consolidation: Given market concentration, mid-sized and smaller players should prepare for acquisition or partnership—while larger incumbents should evaluate inorganic options to fill technology or access gaps.

Conclusion and next steps

2026 will be a pivotal year for ABUS adoption. Regulatory clarity, state-level reimbursement expansions, and rapid product innovation are converging to expand the market opportunity materially over the next decade. Companies that align product development, payer engagement and field service capacity now will capture disproportionate share as the market grows at an expected 9.2% CAGR.

PW Consulting’s full Automatic Breast Ultrasound Imaging System Market report provides the detailed segmentation, commercial playbooks, and financial models necessary to convert these broad trends into executable strategies. For executives preparing capital allocation, product roadmaps, or M&A pipelines in 2026, the report is designed to be a practical guidebook—complete with downloadable models and scenario analyses.

Contact PW Consulting or visit our report page to access the full study and the underlying datasets that support our forecast and strategic recommendations.

For detailed analysis of this topic, please visit the official page: Automatic Breast Ultrasound Imaging System Market

Lacy Lee
Senior Marketing Manager
sales@pmarketresearch.com
00852-95632430
PW Consulting: www.pmarketresearch.com